

Mitchell Sabloff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2453158/publications.pdf>

Version: 2024-02-01

113
papers

3,199
citations

172457
29
h-index

161849
54
g-index

114
all docs

114
docs citations

114
times ranked

4346
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Autologous Hematopoietic Stem Cell Transplantation for Liver Transplant Recipients With Recurrent Primary Sclerosing Cholangitis: A Pilot Study. <i>Transplantation</i> , 2022, 106, 562-574. | 1.0 | 7 |
| 2 | The impact of oral hypoglycemics and statins on outcomes in myelodysplastic syndromes. <i>Annals of Hematology</i> , 2022, 101, 1023-1030. | 1.8 | 3 |
| 3 | Total Body Irradiation for Hematopoietic Stem Cell Transplantation: What Can We Agree on?. <i>Current Oncology</i> , 2021, 28, 903-917. | 2.2 | 29 |
| 4 | Nelarabine-containing regimen followed by daratumumab as an effective salvage therapy and bridge to allogeneic hematopoietic stem cell transplantation for primary refractory early T-cell precursor lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2021, 62, 2295-2297. | 1.3 | 7 |
| 5 | Patient-reported fatigue refines prognosis in higher-risk myelodysplastic syndromes (MDS): a MDS-CAN study. <i>British Journal of Haematology</i> , 2021, 194, 319-324. | 2.5 | 6 |
| 6 | Breaking the Age Barrier: Physicians' Perceptions of Candidacy for Allogeneic Hematopoietic Cell Transplantation in Older Adults. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 617.e1-617.e7. | 1.2 | 14 |
| 7 | Fludarabine and Melphalan Compared with Reduced Doses of Busulfan and Fludarabine Improve Transplantation Outcomes in Older Patients with Myelodysplastic Syndromes. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 921.e1-921.e10. | 1.2 | 11 |
| 8 | The Impact of Oral Hypoglycemics and Statins on Outcomes in Myelodysplastic Syndromes. <i>Blood</i> , 2021, 138, 3064-3064. | 1.4 | 1 |
| 9 | An MDS-specific frailty index based on cumulative deficits adds independent prognostic information to clinical prognostic scoring. <i>Leukemia</i> , 2020, 34, 1394-1406. | 7.2 | 23 |
| 10 | A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 2139-2146. | 2.0 | 14 |
| 11 | Plerixafor in combination with chemotherapy and/or hematopoietic cell transplantation to treat acute leukemia: A systematic review and metanalysis of preclinical and clinical studies. <i>Leukemia Research</i> , 2020, 97, 106442. | 0.8 | 15 |
| 12 | Revised 15-item MDS-specific frailty scale maintains prognostic potential. <i>Leukemia</i> , 2020, 34, 3434-3438. | 7.2 | 8 |
| 13 | Selecting the optimal targeted therapy for relapsed B-acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2020, 61, 2271-2273. | 1.3 | 0 |
| 14 | Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, S161. | 2.0 | 0 |
| 15 | Total body irradiation (18%Gy) without chemotherapy as conditioning for allogeneic hematopoietic cell transplantation in refractory acute myeloid leukemia. <i>Bone Marrow Transplantation</i> , 2020, 55, 1454-1456. | 2.4 | 2 |
| 16 | Clinical Efficacy and Safety of Oral Decitabine/Cedazuridine in 133 Patients with Myelodysplastic Syndromes (MDS) and Chronic Myelomonocytic Leukemia (CMML). <i>Blood</i> , 2020, 136, 37-38. | 1.4 | 16 |
| 17 | High Doses of Targeted Radiation with Anti-CD45 Iodine (131I) Apamistamab [lomab-B] Do Not Correlate with Incidence of Mucositis, Febrile Neutropenia or Sepsis in the Prospective, Randomized Phase 3 Sierra Trial for Patients with Relapsed or Refractory Acute Myeloid Leukemia. <i>Blood</i> , 2020, 136, 30-31. | 1.4 | 2 |
| 18 | Personalized Targeted Radioimmunotherapy with Anti-CD45 Iodine (131I) Apamistamab [lomab-B] in Patients with Active Relapsed or Refractory Acute Myeloid Leukemia Results in Successful Donor Hematopoietic Cells Engraftment with the Timing of Engraftment Not Related to the Radiation Dose Delivered. <i>Blood</i> , 2020, 136, 42-44. | 1.4 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Inferior Outcomes with a High LSC17 Score Can be Improved with Flag-IDA. Blood, 2020, 136, 35-36. | 1.4 | 0 |
| 20 | Fatigue, However Measured, Continues to Refine Prognosis in Higher Risk MDS: An MDS-CAN Study. Blood, 2020, 136, 41-43. | 1.4 | 1 |
| 21 | High Transfusion Dependence and Serum Ferritin but Not Transferrin Saturation Predict Inferior Clinical Outcomes in Patients with MDS. Blood, 2020, 136, 47-48. | 1.4 | 0 |
| 22 | Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2019, 25, 2398-2407. | 2.0 | 21 |
| 23 | Evaluating dose-limiting toxicities of MDM2 inhibitors in patients with solid organ and hematologic malignancies: A systematic review of the literature. Leukemia Research, 2019, 86, 106222. | 0.8 | 12 |
| 24 | Re-Induction and Targeted Conditioning with Anti-CD45 Iodine (131I) Apamistamab [lomab-B] Leads to High Rates of Transplantation and Successful Engraftment in Older Patients with Active, Relapsed or Refractory (rel/ref) AML after Failure of Chemotherapy and Targeted Agents: Preliminary Midpoint Results from the Prospective, Randomized Phase 3 Sierra Trial. Blood, 2019, 134, 5642-5642. | 1.4 | 3 |
| 25 | Pharmacokinetic Exposure Equivalence and Preliminary Efficacy and Safety from a Randomized Cross over Phase 3 Study (ASCERTAIN study) of an Oral Hypomethylating Agent ASTX727 (cedazuridine/decitabine) Compared to IV Decitabine. Blood, 2019, 134, 846-846. | 1.4 | 55 |
| 26 | Prognostic Performance of Frailty Measures in MDS Patients Treated with Hypomethylating Agents. Blood, 2019, 134, 4245-4245. | 1.4 | 3 |
| 27 | Trial in Progress: Feasibility and Validation Study of the LSC17 Score in Acute Myeloid Leukemia Patients. Blood, 2019, 134, 2682-2682. | 1.4 | 6 |
| 28 | Acute Myeloid Leukemia (AML) Treated with Azacitidine: Survival Outcomes for Patients Who Complete More Than Six Cycles Are Similar to High-Risk Myelodysplastic Syndrome/Low Blast Count AML. Blood, 2019, 134, 5156-5156. | 1.4 | 0 |
| 29 | Persistent Red Blood Cell (RBC) Transfusion Is Associated with Increased Mortality Risk in Transfusion-Dependent (TD) Patients with Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS+). Blood, 2019, 134, 3012-3012. | 1.4 | 0 |
| 30 | Intermediate Vs High Dose Busulfan-Based Conditioning for Allogeneic Cell Transplantation in Patients with Acute Leukemia or Myelodysplastic Syndromes from HLA Matched Related or Unrelated Donors: Achieving the Same with Less. Blood, 2019, 134, 3263-3263. | 1.4 | 0 |
| 31 | Intermittent Transfusion Independence Is Associated with Improved Overall Survival in Patients with Transfusion Dependent MDS. Blood, 2019, 134, 5416-5416. | 1.4 | 1 |
| 32 | Long-term graft function following autologous hematopoietic cell transplantation and the impact of preemptive plerixafor in predicted poor mobilizers. Blood Cancer Journal, 2018, 8, 14. | 6.2 | 3 |
| 33 | Rapid Decrease in KRT14 and TP53 mRNA Expression in the Buccal Mucosa of Patients Receiving Total-Body Irradiation for Allogeneic Stem Cell Transplantation. Radiation Research, 2018, 189, 213-218. | 1.5 | 2 |
| 34 | Intravenous Busulfan Compared with Total Body Irradiation Pretransplant Conditioning for Adults with Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 726-733. | 2.0 | 71 |
| 35 | A Dose Escalation Study of Total Marrow Irradiation and Autologous Stem-Cell Transplantation for Relapsed Multiple Myeloma Patients. Biology of Blood and Marrow Transplantation, 2018, 24, S127. | 2.0 | 2 |
| 36 | Effect of Donor Age and Donor Relatedness on Time to Allogeneic Hematopoietic Cell Transplantation in Acute Leukemia. Biology of Blood and Marrow Transplantation, 2018, 24, 2466-2470. | 2.0 | 7 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy. <i>Cancer Discovery</i> , 2018, 8, 1376-1389. | 9.4 | 40 |
| 38 | Health Related Quality of Life Remains Stable over Time in Myelodysplastic Syndrome: An MDS-CAN Prospective Study. <i>Blood</i> , 2018, 132, 4850-4850. | 1.4 | 2 |
| 39 | Targeting the MTF2-MDM2 Axis Sensitizes Refractory Acute Myeloid Leukemia to Chemotherapy. <i>Blood</i> , 2018, 132, 5232-5232. | 1.4 | 0 |
| 40 | Reduced Intensity Conditioned Sibling Transplantation Versus No Transplant in Intermediate or High Risk Acute Myeloid Leukemia: A Prospective Multi-Center Study in Patients 50-70 Years in First Complete Remission and with at Least One Potential Sibling Donor (ClinTrialGov 00342316). <i>Blood</i> , 2018, 132, 205-205. | 1.4 | 2 |
| 41 | Allogeneic Hematopoietic Cell Transplantation for Adult Chronic Myelomonocytic Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 767-775. | 2.0 | 41 |
| 42 | Outcomes Associated with Reducing the Urine Alkalinization Threshold in Patients Receiving High-Dose Methotrexate. <i>Pharmacotherapy</i> , 2017, 37, 684-691. | 2.6 | 20 |
| 43 | High Dose Total Body Irradiation for Refractory Acute Myeloid Leukemia. <i>International Journal of Radiation Oncology Biology Physics</i> , 2017, 99, S179. | 0.8 | 0 |
| 44 | Acute myeloid leukaemia disrupts endogenous myelo-erythropoiesis by compromising the adipocyte bone marrow niche. <i>Nature Cell Biology</i> , 2017, 19, 1336-1347. | 10.3 | 150 |
| 45 | A predictive model of response to erythropoietin stimulating agents in myelodysplastic syndrome: from the Canadian MDS patient registry. <i>Annals of Hematology</i> , 2017, 96, 2025-2029. | 1.8 | 12 |
| 46 | Low-Dose Antithymocyte Globulin for Graft-versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 2096-2101. | 2.0 | 27 |
| 47 | Micro-RNA Profiling of Exosomes from Marrow-Derived Mesenchymal Stromal Cells in Patients with Acute Myeloid Leukemia: Implications in Leukemogenesis. <i>Stem Cell Reviews and Reports</i> , 2017, 13, 817-825. | 5.6 | 65 |
| 48 | ITACA: A new validated international erythropoietic stimulating agent's response score that further refines the predictive power of previous scoring systems. <i>American Journal of Hematology</i> , 2017, 92, 1037-1046. | 4.1 | 20 |
| 49 | MDS-Can-It: A New Validated International ESA-Response Score that Further Refines the Predictive Power of the Nordic Scoring System. <i>Leukemia Research</i> , 2017, 55, S131-S132. | 0.8 | 0 |
| 50 | Overall survival in lower <sc>IPSS</sc> risk <sc>MDS</sc> by receipt of iron chelation therapy, adjusting for patient's related factors and measuring from time of first red blood cell transfusion dependence: an <sc>MDS</sc>â€<sc>CAN</sc> analysis. <i>British Journal of Haematology</i> , 2017, 179, 83-97. | 2.5 | 48 |
| 51 | Increasing use of allogeneic hematopoietic cell transplantation in patients aged 70 years and older in the United States. <i>Blood</i> , 2017, 130, 1156-1164. | 1.4 | 210 |
| 52 | Total Body Irradiation without Chemotherapy as Conditioning for an Allogeneic Hematopoietic Cell Transplantation for Adult Acute Myeloid Leukemia. <i>Case Reports in Hematology</i> , 2016, 2016, 1-7. | 0.4 | 2 |
| 53 | Patient's related factors independently impact overall survival in patients with myelodysplastic syndromes: an <sc>MDS</sc>â€<sc>CAN</sc> prospective study. <i>British Journal of Haematology</i> , 2016, 174, 88-101. | 2.5 | 78 |
| 54 | Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. <i>Cancer</i> , 2016, 122, 3005-3014. | 4.1 | 45 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | Myasthenia Gravis Treated With Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurology, 2016, 73, 652. | 9.0 | 71 |
| 56 | Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome. Journal of Clinical Oncology, 2016, 34, 1864-1871. | 1.6 | 61 |
| 57 | Total Body Irradiation in Relapsed Follicular Lymphoma: Outcomes and Early Toxicity. International Journal of Radiation Oncology Biology Physics, 2016, 96, E498-E499. | 0.8 | 1 |
| 58 | PO-0667: Second malignancies after TBI in AHCT for relapsed follicular lymphoma. Radiotherapy and Oncology, 2016, 119, S311. | 0.6 | 1 |
| 59 | 83: Late Toxicity after TBI in AHCT for Relapsed Follicular Lymphoma. Radiotherapy and Oncology, 2016, 120, S32-S33. | 0.6 | 1 |
| 60 | Rationale and design of platelet transfusions in haematopoietic stem cell transplantation: the PATH pilot study. BMJ Open, 2016, 6, e013483. | 1.9 | 6 |
| 61 | Immunoablation and autologous haemopoietic stem-cell transplantation for aggressive multiple sclerosis: a multicentre single-group phase 2 trial. Lancet, The, 2016, 388, 576-585. | 13.7 | 296 |
| 62 | Adipogenic Mesenchymal Stromal Cells from Bone Marrow and Their Hematopoietic Supportive Role: Towards Understanding the Permissive Marrow Microenvironment in Acute Myeloid Leukemia. Stem Cell Reviews and Reports, 2016, 12, 235-244. | 5.6 | 34 |
| 63 | Duration of first remission and hematopoietic cell transplantation-specific comorbidity index but not age predict survival of patients with AML transplanted in CR2: a retrospective multicenter study. Bone Marrow Transplantation, 2016, 51, 1019-1021. | 2.4 | 5 |
| 64 | Factors Influencing Long-Term Hematopoietic Function Following Autologous Stem Cell Transplantation. Blood, 2016, 128, 2186-2186. | 1.4 | 0 |
| 65 | Quality of Life Scores Improve with Increasing Hemoglobin but Optimal Thresholds Vary According to Transfusion Dependence and Clinical Risk Scores: A Canadian Cross Sectional Study of 689 Patients with 2969 Measurements. Blood, 2016, 128, 3192-3192. | 1.4 | 0 |
| 66 | Low-Dose Anti-Thymocyte Globulin for Graft-Versus-Host-Disease Prophylaxis in Matched Unrelated Allogeneic Hematopoietic Stem Cell Transplant. Blood, 2016, 128, 5782-5782. | 1.4 | 1 |
| 67 | Impact of platelet transfusion on toxicity and mortality after hematopoietic progenitor cell transplantation. Transfusion, 2015, 55, 253-258. | 1.6 | 14 |
| 68 | Mesenchymal stromal cells from patients with acute myeloid leukemia have altered capacity to expand differentiated hematopoietic progenitors. Leukemia Research, 2015, 39, 486-493. | 0.8 | 56 |
| 69 | A single-institution analysis of the utility of pre-induction ejection fraction measurement in patients newly diagnosed with acute myeloid leukemia. Leukemia and Lymphoma, 2015, 56, 135-140. | 1.3 | 6 |
| 70 | Iron Chelation Is Associated with Improved Survival Adjusting for Disease and Patient Related Characteristics in Low/Int-1 Risk MDS at the Time of First Transfusion Dependence: A MDS-CAN Study. Blood, 2015, 126, 1701-1701. | 1.4 | 4 |
| 71 | Acute promyelocytic leukaemia is characterized by stable incidence and improved survival that is restricted to patients managed in leukaemia referral centres: a pan-Canadian epidemiological study. British Journal of Haematology, 2014, 166, 660-666. | 2.5 | 52 |
| 72 | Systemic mastocytosis emerging after azacitidine treatment of refractory anaemia with excess blasts type 2. British Journal of Haematology, 2014, 167, 147-147. | 2.5 | 3 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Autologous Stem Cell Transplantation for Stiff Person Syndrome. JAMA Neurology, 2014, 71, 1296. | 9.0 | 29 |
| 74 | Extended Dose-Total Body Irradiation (18Gy) Followed By an Allogeneic Cell Transplantation for the Treatment of Refractory Acute Myeloid Leukemia: Early Results. Biology of Blood and Marrow Transplantation, 2014, 20, S157-S158. | 2.0 | 0 |
| 75 | Favorable Outcomes from Allogeneic and Autologous Stem Cell Transplantation for Patients with Transformed Nonfollicular Indolent Lymphoma. Biology of Blood and Marrow Transplantation, 2014, 20, 1813-1818. | 2.0 | 16 |
| 76 | Does Total Body Irradiation Conditioning Improve Outcomes of Myeloablative Human Leukocyte Antigenâ€“Identical Sibling Transplantations for Chronic Lymphocytic Leukemia?. Biology of Blood and Marrow Transplantation, 2014, 20, 421-424. | 2.0 | 13 |
| 77 | Effect of Postremission Therapy before Reduced-Intensity Conditioning Allogeneic Transplantation for Acute Myeloid Leukemia in First Complete Remission. Biology of Blood and Marrow Transplantation, 2014, 20, 202-208. | 2.0 | 33 |
| 78 | Outcomes of Human Leukocyte Antigenâ€“Matched Sibling Donor Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia: Myeloablative Versus Reduced-Intensity Conditioning Regimens. Biology of Blood and Marrow Transplantation, 2014, 20, 1390-1398. | 2.0 | 18 |
| 79 | Patient Related Factors Have an Independent Impact on Overall Survival in Myelodysplastic Syndrome Patients: A Report of the MDS-Can Registry. Blood, 2014, 124, 165-165. | 1.4 | 1 |
| 80 | Autologous Stem Cell Transplant for Myasthenia Gravis: A Single-Centre Experience. Blood, 2014, 124, 3996-3996. | 1.4 | 16 |
| 81 | P-116 Frailty is an independent prognostic marker for overall survival in MDS: Results of a Canadian MDS registry. Leukemia Research, 2013, 37, S76. | 0.8 | 0 |
| 82 | Autologous and Allogeneic Stem-Cell Transplantation for Transformed Follicular Lymphoma: A Report of the Canadian Blood and Marrow Transplant Group. Journal of Clinical Oncology, 2013, 31, 1164-1171. | 1.6 | 92 |
| 83 | Better leukemia-free and overall survival in AML in first remission following cyclophosphamide in combination with busulfan compared with TBI. Blood, 2013, 122, 3863-3870. | 1.4 | 153 |
| 84 | Who is the better donor for older hematopoietic transplant recipients: an older-aged sibling or a young, matched unrelated volunteer?. Blood, 2013, 121, 2567-2573. | 1.4 | 120 |
| 85 | Acute Promyelocytic Leukemia In Canada: Poor Outcomes In Older Patients Remain. Blood, 2013, 122, 1714-1714. | 1.4 | 0 |
| 86 | Serial assessment of toxicity after hematopoietic SCT can discern kinetics of transplant-related organ injury and patterns of recovery. Bone Marrow Transplantation, 2012, 47, 1375-1376. | 2.4 | 1 |
| 87 | Vascular access devices in leukemia: a retrospective review amongst patients treated at The Ottawa Hospital with induction chemotherapy for acute leukemia. Leukemia and Lymphoma, 2012, 53, 1090-1095. | 1.3 | 19 |
| 88 | Outcomes of Allogeneic Hematopoietic Cell Transplantation (HCT) in Chronic Lymphocytic Leukemia (CLL): Impact of Myeloablative (MA) Vs. Reduced-Intensity Conditioning (RIC) Regimens, and Impact of Total Body Irradiation (TBI)-Based MA Versus Chemotherapy (CT)-Based MA Conditioning. Biology of Blood and Marrow Transplantation, 2012, 18, S290-S291. | 2.0 | 0 |
| 89 | Utility of Pre-Induction Cardiac Function Testing in Patients with Newly Diagnosed AML. Blood, 2012, 120, 2068-2068. | 1.4 | 0 |
| 90 | Comparison of Outcomes after Transplantation of G-CSFâ€“Stimulated Bone Marrow Grafts versus Bone Marrow or Peripheral Blood Grafts from HLA-Matched Sibling Donors for Patients with Severe Aplastic Anemia. Biology of Blood and Marrow Transplantation, 2011, 17, 1018-1024. | 2.0 | 60 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 91 | HLA-matched sibling bone marrow transplantation for β^2 -thalassemia major. Blood, 2011, 117, 1745-1750. | 1.4 | 114 |
| 92 | Retrospective Review of Invasive Fungal Disease in a Cohort of Patients with Acute Leukemia. Blood, 2011, 118, 4265-4265. | 1.4 | 7 |
| 93 | Impact of age on outcomes after bone marrow transplantation for acquired aplastic anemia using HLA-matched sibling donors. Haematologica, 2010, 95, 2119-2125. | 3.5 | 137 |
| 94 | The outcome of full-intensity and reduced-intensity conditioning matched sibling or unrelated donor transplantation in adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first and second complete remission. Blood, 2010, 116, 366-374. | 1.4 | 178 |
| 95 | Comparable survival after HLA-well-matched unrelated or matched sibling donor transplantation for acute myeloid leukemia in first remission with unfavorable cytogenetics at diagnosis. Blood, 2010, 116, 1839-1848. | 1.4 | 168 |
| 96 | Monoclonal B cells detected in autologous PBSC grafts from patients with classical Hodgkin lymphoma: impact on relapse and survival following transplantation. Bone Marrow Transplantation, 2010, 45, 856-861. | 2.4 | 0 |
| 97 | The Impact Of Prior Exposure To Rituximab On Autologous Stem Cell Transplantation In Patients With Follicular And Transformed Lymphoma. Biology of Blood and Marrow Transplantation, 2010, 16, S198. | 2.0 | 0 |
| 98 | Contaminating tumour cells in autologous PBSC grafts do not influence survival or relapse following transplant for multiple myeloma or B-cell non-Hodgkin's lymphoma. Bone Marrow Transplantation, 2009, 43, 223-228. | 2.4 | 31 |
| 99 | A retrospective comparison of conventional intensity conditioning and reduced-intensity conditioning for allogeneic hematopoietic cell transplantation in myelofibrosis. Bone Marrow Transplantation, 2009, 44, 317-320. | 2.4 | 49 |
| 100 | Bone Marrow Transplantation From HLA-Identical Sibling for Thalassemia.. Blood, 2009, 114, 3361-3361. | 1.4 | 1 |
| 101 | The Impact of Prior Exposure to Rituximab On Autologous Stem Cell Transplantation in Patients with Follicular and Transformed Follicular Lymphoma.. Blood, 2009, 114, 1230-1230. | 1.4 | 0 |
| 102 | Vascular Access Devices: A Retrospective Review Amongst Patients Treated at the Ottawa Hospital with Induction Chemotherapy for Acute Leukemia.. Blood, 2009, 114, 4521-4521. | 1.4 | 0 |
| 103 | Unrelated donor transplants in adults with Philadelphia-negative acute lymphoblastic leukemia in first complete remission. Blood, 2008, 112, 426-434. | 1.4 | 80 |
| 104 | Hematopoietic Recovery and Overall Survival after HLA-Matched Sibling Transplants for Older Patients with Severe Aplastic Anemia (SAA).. Blood, 2008, 112, 2169-2169. | 1.4 | 1 |
| 105 | A 15-Year Analysis of Early and Late Autologous Hematopoietic Stem Cell Transplant in Relapsed, Aggressive, Transformed, and Nontransformed Follicular Lymphoma. Biology of Blood and Marrow Transplantation, 2007, 13, 956-964. | 2.0 | 56 |
| 106 | Impact of Conditioning on the Outcome of Allografting in Myelofibrosis with Myeloid Metaplasia: Better Survival with Reduced Intensity Approach in Patients ≥ 50 Years.. Blood, 2007, 110, 1095-1095. | 1.4 | 0 |
| 107 | A 15-year review of autologous stem cell transplant of advanced relapsed follicular lymphoma at the Ottawa hospital. Biology of Blood and Marrow Transplantation, 2006, 12, 115. | 2.0 | 0 |
| 108 | Outpatient autologous hematopoietic stem cell transplantation for patients with relapsed follicular lymphoma. Annals of Hematology, 2006, 85, 723-729. | 1.8 | 27 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 109 | Percent of Peripheral Blood Leukemic Blasts (PPBLB) at Diagnosis as a Predictor of Short- and Long-Term Survival in Acute Myeloid Leukemia (AML).. Blood, 2006, 108, 4449-4449. | 1.4 | 0 |
| 110 | A Randomized Trial Comparing the Effectiveness of Peripheral Blood Stem Cell Mobilization with Chemotherapy and Early vs Delayed Initiation of Granulocyte Colony-Stimulating Factor (G-CSF) in Patients with Lymphoma and Multiple Myeloma.. Blood, 2005, 106, 2929-2929. | 1.4 | 0 |
| 111 | The effect of plasmapheresis on the serum activity level of dalteparin: a case report. Blood Coagulation and Fibrinolysis, 2000, 11, 395-400. | 1.0 | 15 |
| 112 | Use of recombinant-hirudin in pulmonary thromboendarterectomy. Annals of Thoracic Surgery, 2000, 69, 1942-1943. | 1.3 | 14 |
| 113 | Anti-cruciform DNA affinity purification of active mammalian origins of replication. Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 1991, 1089, 299-308. | 2.4 | 28 |